In “Acknowledgments” on page 604, support from the National Institutes of Health for Jeffrey A. Zonder (grant P30 CA022453) is not acknowledged. The error has been corrected in the online version of the article.
Erratum: A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis (Blood (2017)130: 5 (597-605)DOI: 10.1182/blood-2017-03-771220)
Palladini, G;
2020-01-01
Abstract
In “Acknowledgments” on page 604, support from the National Institutes of Health for Jeffrey A. Zonder (grant P30 CA022453) is not acknowledged. The error has been corrected in the online version of the article.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
